Invention Grant
- Patent Title: 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
-
Application No.: US16547037Application Date: 2019-08-21
-
Publication No.: US10723711B2Publication Date: 2020-07-28
- Inventor: Christopher Ryan Butler , Laura Ann McAllister , Elizabeth Mary Beck , Michael Aaron Brodney , Adam Matthew Gilbert , Christopher John Helal , Douglas Scott Johnson , Justin Ian Montgomery , Steven Victor O'Neil , Bruce Nelsen Rogers , Patrick Robert Verhoest , Damien Webb
- Applicant: PFIZER INC.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- Agent Feng Shao
- Main IPC: C07D295/14
- IPC: C07D295/14 ; C07D401/14 ; C07D401/04 ; C07D403/04 ; C07D498/10 ; C07D491/107 ; C07D401/12 ; C07D471/10 ; C07D487/04 ; C07D211/48 ; C07D471/08 ; C07D515/10 ; C07F9/6561 ; C07D405/14 ; C07D413/14 ; C07D405/12 ; C07D493/10
Abstract:
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
Public/Granted literature
Information query
